



## Test Definition: THSIF

Thrombospondin Type 1 Domain Containing 7A (THSD7A), Immunofluorescence

---

### Overview

#### Useful For

Diagnosis of thrombospondin type 1 domain-containing 7A (THSD7A)-associated membranous nephropathy

#### Method Name

Direct Immunofluorescence (DIF)

#### NY State Available

Yes

### Specimen

#### Specimen Type

Special

#### Ordering Guidance

If additional interpretation/analysis is needed, request PATHC / Pathology Consultation along with this test and send the corresponding renal pathology light microscopy and immunofluorescence (IF) slides (or IF images on a CD), electron microscopy images (prints or CD), and the pathology report.

#### Necessary Information

**A preliminary pathology report is required for testing to be performed.** Send information with specimen. The laboratory will not reject testing if a reason for testing is not provided; however appropriate testing and interpretation may be compromised or delayed. If not provided, an appropriate indication for testing may be entered by Mayo Clinic Laboratories.

#### Specimen Required

**Specimen Type:** Kidney tissue

**Preferred:** 2 Unstained positively charged glass slide (25- x 75- x 1-mm) per test ordered; paraffin sections 3 to 4-microns thick

**Acceptable:** Formalin-fixed, paraffin-embedded (FFPE) kidney tissue block

#### Forms

If not ordering electronically, complete, print, and send 1 of the following forms with the specimen:

[-Kidney Transplant Test Request](#)

[-Renal Diagnostics Test Request](#) (T830)

#### Specimen Minimum Volume

See Specimen Required

**Reject Due To**

All specimens will be evaluated at Mayo Clinic Laboratories for test suitability.

**Specimen Stability Information**

Specimen Type	Temperature	Time	Special Container
Special	Ambient (preferred)		
	Refrigerated		
	Frozen		

**Clinical & Interpretive****Clinical Information**

Thrombospondin type 1 domain-containing 7A (THSD7A) is a target antigen in membranous nephropathy (MN) and is detected in approximately 3% to 5% of non- phospholipase A2 receptor (PLA2R)-associated MN patients. Differentiating THSD7A-associated MN from PLA2R-associated MN is critical as approximately 20% of patients with THSD7A-associated MN have solid malignancy suggesting that THSD7A-associated MN is more likely to be secondary to malignancy than PLA2R-associated MN.

**Interpretation**

Staining is interpreted and reported as negative or positive.

**Cautions**

No significant cautionary statements

**Clinical Reference**

- Hoxha E, Beck Jr LH, Wiech T et al. An indirect immunofluorescence method facilitates detection of thrombospondin type 1 domain-containing 7A-specific antibodies in membranous nephropathy. *J Am Soc Nephrol.* 2017;28:520-531
- Larsen CP, Cossey LN, Bech LH. THSD7A staining of membranous glomerulopathy in clinical practice reveals cases with dual autoantibody positivity. *Mod Pathol.* 2016;29:421-426
- Sharma SG, Larsen CP: Tissue staining for THSD7A in glomeruli correlates with serum antibodies in primary membranous nephropathy: a clinicopathological study. *Mod Pathol.* 2018;31(4):616-622

**Performance****Method Description**

Direct immunofluorescence staining on sections of formalin-fixed, paraffin-embedded kidney tissue.(Unpublished Mayo method)

**PDF Report**

No

**Day(s) Performed**

Monday through Friday

**Report Available**

1 to 2 days

**Specimen Retention Time**

Until reported

**Performing Laboratory Location**

Mayo Clinical Laboratories- Rochester Main Campus

**Fees & Codes****Fees**

- Authorized users can sign in to [Test Prices](#) for detailed fee information.
- Clients without access to Test Prices can contact [Customer Service](#) 24 hours a day, seven days a week.
- Prospective clients should contact their account representative. For assistance, contact [Customer Service](#).

**Test Classification**

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

**CPT Code Information**

88346-Primary IF

88350-If additional IF

**LOINC® Information**

Test ID	Test Order Name	Order LOINC® Value
THSIF	THSD7A Immunofluorescence	101116-2

Result ID	Test Result Name	Result LOINC® Value
605245	Interpretation	50595-8
606383	Participated in the Interpretation	No LOINC Needed
606384	Report electronically signed by	19139-5
606385	Addendum	35265-8
606386	Gross Description	22634-0
606387	Material Received	22633-2
606388	Disclaimer	62364-5
606389	Case Number	80398-1